12:00 AM
Jun 13, 2011
 |  BC Week In Review  |  Company News  |  Deals

Seattle Genetics, Astellas deal

Seattle Genetics exercised a 2007 option from Astellas' Agensys Inc. subsidiary to co-develop and co-commercialize ASG-22ME. Agensys submitted an IND last quarter for a Phase I...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD